Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor.

作者信息

Chassagnon Guillaume, Hubert Dominique, Fajac Isabelle, Burgel Pierre-Régis, Revel Marie-Pierre

机构信息

Radiology Dept, Cochin Hospital, AP-HP, Paris, France Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

Université Paris Descartes, Sorbonne Paris Cité, Paris, France Pulmonary Dept and Adult CF Centre, Cochin Hospital, AP-HP, Paris, France.

出版信息

Eur Respir J. 2016 Jul;48(1):249-52. doi: 10.1183/13993003.01918-2015. Epub 2016 May 26.

DOI:10.1183/13993003.01918-2015

PMID:27230445

Abstract

摘要

相似文献

Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor.

Eur Respir J. 2016 Jul;48(1):249-52. doi: 10.1183/13993003.01918-2015. Epub 2016 May 26.

Therapeutic benefit of ivacaftor in late cystic fibrosis caused by homozygous IVS8-5T CFTR polymorphism.依伐卡托对纯合子IVS8-5T囊性纤维化跨膜传导调节因子（CFTR）基因多态性所致晚期囊性纤维化的治疗益处。

J Cyst Fibros. 2017 Jan;16(1):89-90. doi: 10.1016/j.jcf.2016.10.008. Epub 2016 Oct 31.

Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.恢复囊性纤维化跨膜传导调节因子功能可减少囊性纤维化和慢性肺部感染患者的气道细菌及炎症。

Am J Respir Crit Care Med. 2017 Jun 15;195(12):1617-1628. doi: 10.1164/rccm.201609-1954OC.

CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor.囊性纤维化 CORK 研究：伊伐卡托调节囊性纤维化跨膜传导调节因子后超低剂量胸部 CT 评分的持续改善。

Chest. 2018 Feb;153(2):395-403. doi: 10.1016/j.chest.2017.10.005. Epub 2017 Oct 14.

Treating Specific Variants Causing Cystic Fibrosis.治疗导致囊性纤维化的特定变体。

JAMA. 2017 Dec 5;318(21):2130-2131. doi: 10.1001/jama.2017.16823.

Potentiators for cystic fibrosis - targeting the underlying molecular defect.囊性纤维化的增效剂——针对潜在分子缺陷

Paediatr Respir Rev. 2015 Jun;16(3):162-4. doi: 10.1016/j.prrv.2015.04.003. Epub 2015 Apr 20.

CT imaging of pediatric patients with cystic fibrosis on ivacaftor therapy.接受依伐卡托治疗的囊性纤维化儿科患者的CT成像

Lung. 2014 Oct;192(5):823-4. doi: 10.1007/s00408-014-9629-y. Epub 2014 Aug 7.

Ivacaftor and Airway Inflammation in Preschool Children with Cystic Fibrosis.依伐卡托与囊性纤维化学龄前儿童的气道炎症

Am J Respir Crit Care Med. 2021 Sep 1;204(5):605-608. doi: 10.1164/rccm.202012-4332LE.

The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients.依伐卡托对 S1251N 介导的囊性纤维化患者鼻窦病理的影响。

PLoS One. 2020 Jul 20;15(7):e0235638. doi: 10.1371/journal.pone.0235638. eCollection 2020.

Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement.依伐卡托治疗的囊性纤维化患者虽无短期临床改善，但仍获得长期益处。

Am J Respir Crit Care Med. 2018 Jun 1;197(11):1483-1486. doi: 10.1164/rccm.201710-2046LE.

引用本文的文献

Evolution of Lung Disease Studied by Computed Tomography in Adults with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor.接受依列卡福妥/替扎卡福妥/依伐卡托治疗的成年囊性纤维化患者肺部疾病的计算机断层扫描研究进展

J Imaging. 2025 Apr 21;11(4):124. doi: 10.3390/jimaging11040124.

Qualitative and quantitative evaluation of computed tomography changes in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: a retrospective observational study.接受依列卡福妥-替扎卡福妥-依伐卡托治疗的成年囊性纤维化患者计算机断层扫描变化的定性和定量评估：一项回顾性观察研究

Front Pharmacol. 2023 Sep 21;14:1245885. doi: 10.3389/fphar.2023.1245885. eCollection 2023.

The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6-11 with cystic fibrosis in a real-world setting.在真实环境中，Lumacaftor-Ivacaftor 对 6-11 岁患有囊性纤维化的儿童结构性肺病和肺功能的临床影响。

Respir Res. 2023 Aug 11;24(1):199. doi: 10.1186/s12931-023-02497-0.

The effect of CFTR modulators on structural lung disease in cystic fibrosis.囊性纤维化跨膜传导调节因子调节剂对囊性纤维化患者肺部结构疾病的影响。

Front Pharmacol. 2023 Apr 11;14:1147348. doi: 10.3389/fphar.2023.1147348. eCollection 2023.

Role of inhaled antibiotics in the era of highly effective CFTR modulators.在高效 CFTR 调节剂时代吸入抗生素的作用。

Eur Respir Rev. 2023 Jan 11;32(167). doi: 10.1183/16000617.0154-2022. Print 2023 Mar 31.

The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation.高效调节剂治疗对囊性纤维化微生物组和炎症的影响。

Clin Chest Med. 2022 Dec;43(4):647-665. doi: 10.1016/j.ccm.2022.06.007.

CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France.囊性纤维化患者的 CFTR 调节剂：法国的真实世界证据。

Cells. 2022 May 28;11(11):1769. doi: 10.3390/cells11111769.

New Therapies to Correct the Cystic Fibrosis Basic Defect.新型疗法纠正囊性纤维化基础缺陷。

Int J Mol Sci. 2021 Jun 8;22(12):6193. doi: 10.3390/ijms22126193.

Computed Tomographic Changes in Patients with Cystic Fibrosis Treated by Combination Therapy with Lumacaftor and Ivacaftor.接受鲁马卡托和依伐卡托联合治疗的囊性纤维化患者的计算机断层扫描变化

J Clin Med. 2021 May 7;10(9):1999. doi: 10.3390/jcm10091999.

Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review.依伐卡托治疗囊性纤维化患者的真实世界结局：一项系统评价

J Clin Med. 2021 Apr 6;10(7):1527. doi: 10.3390/jcm10071527.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验